nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—ovarian cancer	0.476	1	CbGaD
Amantadine—ABCB1—Topotecan—ovarian cancer	0.0182	0.354	CbGbCtD
Amantadine—ABCB1—Vinorelbine—ovarian cancer	0.0128	0.249	CbGbCtD
Amantadine—ABCB1—Paclitaxel—ovarian cancer	0.00901	0.175	CbGbCtD
Amantadine—GRIN3B—testis—ovarian cancer	0.00661	0.0927	CbGeAlD
Amantadine—ABCB1—Docetaxel—ovarian cancer	0.00651	0.127	CbGbCtD
Amantadine—ABCB1—Doxorubicin—ovarian cancer	0.00485	0.0944	CbGbCtD
Amantadine—DDC—embryo—ovarian cancer	0.00419	0.0588	CbGeAlD
Amantadine—GRIN2C—testis—ovarian cancer	0.00318	0.0445	CbGeAlD
Amantadine—GRIN2D—testis—ovarian cancer	0.00295	0.0414	CbGeAlD
Amantadine—GRIN3A—testis—ovarian cancer	0.00278	0.0389	CbGeAlD
Amantadine—DDC—female reproductive system—ovarian cancer	0.00254	0.0356	CbGeAlD
Amantadine—GRIN2A—vagina—ovarian cancer	0.00246	0.0345	CbGeAlD
Amantadine—SIGMAR1—myometrium—ovarian cancer	0.00234	0.0328	CbGeAlD
Amantadine—MAOB—myometrium—ovarian cancer	0.00224	0.0314	CbGeAlD
Amantadine—GRIN2A—testis—ovarian cancer	0.0022	0.0308	CbGeAlD
Amantadine—MAOB—embryo—ovarian cancer	0.00216	0.0302	CbGeAlD
Amantadine—DDC—testis—ovarian cancer	0.00205	0.0288	CbGeAlD
Amantadine—SIGMAR1—uterine cervix—ovarian cancer	0.00182	0.0256	CbGeAlD
Amantadine—MAOB—uterine cervix—ovarian cancer	0.00174	0.0245	CbGeAlD
Amantadine—SIGMAR1—decidua—ovarian cancer	0.00174	0.0243	CbGeAlD
Amantadine—MAOB—decidua—ovarian cancer	0.00166	0.0233	CbGeAlD
Amantadine—SIGMAR1—endometrium—ovarian cancer	0.00165	0.0231	CbGeAlD
Amantadine—MAOB—endometrium—ovarian cancer	0.00158	0.0221	CbGeAlD
Amantadine—SIGMAR1—uterus—ovarian cancer	0.00152	0.0213	CbGeAlD
Amantadine—DDC—lymph node—ovarian cancer	0.00149	0.0208	CbGeAlD
Amantadine—MAOB—uterus—ovarian cancer	0.00145	0.0204	CbGeAlD
Amantadine—SLC22A1—vagina—ovarian cancer	0.00134	0.0187	CbGeAlD
Amantadine—MAOB—female reproductive system—ovarian cancer	0.00131	0.0183	CbGeAlD
Amantadine—SIGMAR1—bone marrow—ovarian cancer	0.00129	0.0181	CbGeAlD
Amantadine—SIGMAR1—female gonad—ovarian cancer	0.00124	0.0174	CbGeAlD
Amantadine—SIGMAR1—vagina—ovarian cancer	0.00124	0.0173	CbGeAlD
Amantadine—MAOB—female gonad—ovarian cancer	0.00119	0.0167	CbGeAlD
Amantadine—MAOB—vagina—ovarian cancer	0.00118	0.0166	CbGeAlD
Amantadine—SIGMAR1—testis—ovarian cancer	0.0011	0.0155	CbGeAlD
Amantadine—MAOB—testis—ovarian cancer	0.00106	0.0148	CbGeAlD
Amantadine—DRD2—testis—ovarian cancer	0.00089	0.0125	CbGeAlD
Amantadine—ABCB1—myometrium—ovarian cancer	0.000818	0.0115	CbGeAlD
Amantadine—SIGMAR1—lymph node—ovarian cancer	0.000799	0.0112	CbGeAlD
Amantadine—ABCB1—embryo—ovarian cancer	0.000787	0.011	CbGeAlD
Amantadine—MAOB—lymph node—ovarian cancer	0.000765	0.0107	CbGeAlD
Amantadine—ABCB1—epithelium—ovarian cancer	0.000642	0.009	CbGeAlD
Amantadine—ABCB1—uterine cervix—ovarian cancer	0.000636	0.00892	CbGeAlD
Amantadine—ABCB1—decidua—ovarian cancer	0.000606	0.0085	CbGeAlD
Amantadine—ABCB1—endometrium—ovarian cancer	0.000576	0.00807	CbGeAlD
Amantadine—Pruritus—Topotecan—ovarian cancer	0.000537	0.00204	CcSEcCtD
Amantadine—Photosensitivity—Doxorubicin—ovarian cancer	0.000535	0.00204	CcSEcCtD
Amantadine—Malnutrition—Paclitaxel—ovarian cancer	0.000535	0.00204	CcSEcCtD
Amantadine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000535	0.00204	CcSEcCtD
Amantadine—ABCB1—gonad—ovarian cancer	0.000534	0.00749	CbGeAlD
Amantadine—Asthenia—Melphalan—ovarian cancer	0.000533	0.00203	CcSEcCtD
Amantadine—ABCB1—uterus—ovarian cancer	0.00053	0.00744	CbGeAlD
Amantadine—Pruritus—Melphalan—ovarian cancer	0.000525	0.002	CcSEcCtD
Amantadine—Tension—Paclitaxel—ovarian cancer	0.000525	0.002	CcSEcCtD
Amantadine—Eczema—Doxorubicin—ovarian cancer	0.000523	0.00199	CcSEcCtD
Amantadine—Cardiac failure—Epirubicin—ovarian cancer	0.00052	0.00198	CcSEcCtD
Amantadine—Nervousness—Paclitaxel—ovarian cancer	0.000519	0.00198	CcSEcCtD
Amantadine—Diarrhoea—Topotecan—ovarian cancer	0.000519	0.00198	CcSEcCtD
Amantadine—Lethargy—Epirubicin—ovarian cancer	0.000518	0.00197	CcSEcCtD
Amantadine—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000518	0.00197	CcSEcCtD
Amantadine—Urinary tract disorder—Docetaxel—ovarian cancer	0.000514	0.00196	CcSEcCtD
Amantadine—Body temperature increased—Vinorelbine—ovarian cancer	0.000513	0.00195	CcSEcCtD
Amantadine—Oedema peripheral—Docetaxel—ovarian cancer	0.000513	0.00195	CcSEcCtD
Amantadine—Urethral disorder—Docetaxel—ovarian cancer	0.00051	0.00194	CcSEcCtD
Amantadine—Renal failure acute—Doxorubicin—ovarian cancer	0.000509	0.00194	CcSEcCtD
Amantadine—Diarrhoea—Melphalan—ovarian cancer	0.000508	0.00194	CcSEcCtD
Amantadine—Osteoarthritis—Epirubicin—ovarian cancer	0.000508	0.00193	CcSEcCtD
Amantadine—Nausea—Chlorambucil—ovarian cancer	0.000506	0.00193	CcSEcCtD
Amantadine—Vision blurred—Paclitaxel—ovarian cancer	0.000504	0.00192	CcSEcCtD
Amantadine—Visual impairment—Docetaxel—ovarian cancer	0.000502	0.00191	CcSEcCtD
Amantadine—Dizziness—Topotecan—ovarian cancer	0.000502	0.00191	CcSEcCtD
Amantadine—Tremor—Paclitaxel—ovarian cancer	0.000501	0.00191	CcSEcCtD
Amantadine—Agitation—Paclitaxel—ovarian cancer	0.000491	0.00187	CcSEcCtD
Amantadine—Eye disorder—Docetaxel—ovarian cancer	0.000487	0.00185	CcSEcCtD
Amantadine—Cardiac disorder—Docetaxel—ovarian cancer	0.000483	0.00184	CcSEcCtD
Amantadine—Cardiac arrest—Epirubicin—ovarian cancer	0.000483	0.00184	CcSEcCtD
Amantadine—Vomiting—Topotecan—ovarian cancer	0.000482	0.00184	CcSEcCtD
Amantadine—Cardiac failure—Doxorubicin—ovarian cancer	0.000481	0.00183	CcSEcCtD
Amantadine—Lethargy—Doxorubicin—ovarian cancer	0.000479	0.00183	CcSEcCtD
Amantadine—Leukopenia—Paclitaxel—ovarian cancer	0.000479	0.00182	CcSEcCtD
Amantadine—Rash—Topotecan—ovarian cancer	0.000478	0.00182	CcSEcCtD
Amantadine—Hypersensitivity—Vinorelbine—ovarian cancer	0.000478	0.00182	CcSEcCtD
Amantadine—Dermatitis—Topotecan—ovarian cancer	0.000478	0.00182	CcSEcCtD
Amantadine—Ataxia—Epirubicin—ovarian cancer	0.000477	0.00182	CcSEcCtD
Amantadine—ABCB1—female reproductive system—ovarian cancer	0.000477	0.00669	CbGeAlD
Amantadine—Headache—Topotecan—ovarian cancer	0.000475	0.00181	CcSEcCtD
Amantadine—Palpitations—Paclitaxel—ovarian cancer	0.000473	0.0018	CcSEcCtD
Amantadine—Angiopathy—Docetaxel—ovarian cancer	0.000472	0.0018	CcSEcCtD
Amantadine—Vomiting—Melphalan—ovarian cancer	0.000472	0.0018	CcSEcCtD
Amantadine—Osteoarthritis—Doxorubicin—ovarian cancer	0.00047	0.00179	CcSEcCtD
Amantadine—Mediastinal disorder—Docetaxel—ovarian cancer	0.000469	0.00179	CcSEcCtD
Amantadine—Liver function test abnormal—Epirubicin—ovarian cancer	0.000469	0.00179	CcSEcCtD
Amantadine—Rash—Melphalan—ovarian cancer	0.000468	0.00178	CcSEcCtD
Amantadine—Dermatitis—Melphalan—ovarian cancer	0.000468	0.00178	CcSEcCtD
Amantadine—Asthenia—Vinorelbine—ovarian cancer	0.000466	0.00177	CcSEcCtD
Amantadine—Arrhythmia—Docetaxel—ovarian cancer	0.000465	0.00177	CcSEcCtD
Amantadine—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000464	0.00177	CcSEcCtD
Amantadine—Convulsion—Paclitaxel—ovarian cancer	0.000463	0.00176	CcSEcCtD
Amantadine—Hypertension—Paclitaxel—ovarian cancer	0.000462	0.00176	CcSEcCtD
Amantadine—Alopecia—Docetaxel—ovarian cancer	0.00046	0.00175	CcSEcCtD
Amantadine—Pruritus—Vinorelbine—ovarian cancer	0.000459	0.00175	CcSEcCtD
Amantadine—Mental disorder—Docetaxel—ovarian cancer	0.000456	0.00174	CcSEcCtD
Amantadine—Anxiety—Paclitaxel—ovarian cancer	0.000454	0.00173	CcSEcCtD
Amantadine—Malnutrition—Docetaxel—ovarian cancer	0.000453	0.00173	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000452	0.00172	CcSEcCtD
Amantadine—Nausea—Topotecan—ovarian cancer	0.000451	0.00172	CcSEcCtD
Amantadine—ABCB1—bone marrow—ovarian cancer	0.00045	0.00631	CbGeAlD
Amantadine—Cardiac arrest—Doxorubicin—ovarian cancer	0.000447	0.0017	CcSEcCtD
Amantadine—Dry mouth—Paclitaxel—ovarian cancer	0.000445	0.0017	CcSEcCtD
Amantadine—Diarrhoea—Vinorelbine—ovarian cancer	0.000444	0.00169	CcSEcCtD
Amantadine—Ataxia—Doxorubicin—ovarian cancer	0.000442	0.00168	CcSEcCtD
Amantadine—Nausea—Melphalan—ovarian cancer	0.000441	0.00168	CcSEcCtD
Amantadine—Confusional state—Paclitaxel—ovarian cancer	0.00044	0.00168	CcSEcCtD
Amantadine—Dysphagia—Epirubicin—ovarian cancer	0.000439	0.00167	CcSEcCtD
Amantadine—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000436	0.00166	CcSEcCtD
Amantadine—Oedema—Paclitaxel—ovarian cancer	0.000436	0.00166	CcSEcCtD
Amantadine—ABCB1—female gonad—ovarian cancer	0.000434	0.00608	CbGeAlD
Amantadine—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000434	0.00165	CcSEcCtD
Amantadine—ABCB1—vagina—ovarian cancer	0.000431	0.00605	CbGeAlD
Amantadine—Dizziness—Vinorelbine—ovarian cancer	0.000429	0.00163	CcSEcCtD
Amantadine—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000429	0.00163	CcSEcCtD
Amantadine—Nervous system disorder—Paclitaxel—ovarian cancer	0.000428	0.00163	CcSEcCtD
Amantadine—Tachycardia—Paclitaxel—ovarian cancer	0.000426	0.00162	CcSEcCtD
Amantadine—Skin disorder—Paclitaxel—ovarian cancer	0.000424	0.00161	CcSEcCtD
Amantadine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000422	0.00161	CcSEcCtD
Amantadine—Anorexia—Paclitaxel—ovarian cancer	0.000416	0.00158	CcSEcCtD
Amantadine—Vomiting—Vinorelbine—ovarian cancer	0.000413	0.00157	CcSEcCtD
Amantadine—Neutropenia—Epirubicin—ovarian cancer	0.00041	0.00156	CcSEcCtD
Amantadine—Rash—Vinorelbine—ovarian cancer	0.000409	0.00156	CcSEcCtD
Amantadine—Dermatitis—Vinorelbine—ovarian cancer	0.000409	0.00156	CcSEcCtD
Amantadine—Hypotension—Paclitaxel—ovarian cancer	0.000408	0.00155	CcSEcCtD
Amantadine—Headache—Vinorelbine—ovarian cancer	0.000406	0.00155	CcSEcCtD
Amantadine—Dysphagia—Doxorubicin—ovarian cancer	0.000406	0.00155	CcSEcCtD
Amantadine—Leukopenia—Docetaxel—ovarian cancer	0.000406	0.00155	CcSEcCtD
Amantadine—Palpitations—Docetaxel—ovarian cancer	0.000401	0.00153	CcSEcCtD
Amantadine—Photosensitivity reaction—Epirubicin—ovarian cancer	0.0004	0.00153	CcSEcCtD
Amantadine—Insomnia—Paclitaxel—ovarian cancer	0.000395	0.0015	CcSEcCtD
Amantadine—Convulsion—Docetaxel—ovarian cancer	0.000393	0.0015	CcSEcCtD
Amantadine—Paraesthesia—Paclitaxel—ovarian cancer	0.000392	0.00149	CcSEcCtD
Amantadine—Hypertension—Docetaxel—ovarian cancer	0.000391	0.00149	CcSEcCtD
Amantadine—Dyspnoea—Paclitaxel—ovarian cancer	0.000389	0.00148	CcSEcCtD
Amantadine—Somnolence—Paclitaxel—ovarian cancer	0.000388	0.00148	CcSEcCtD
Amantadine—Nausea—Vinorelbine—ovarian cancer	0.000385	0.00147	CcSEcCtD
Amantadine—ABCB1—testis—ovarian cancer	0.000385	0.0054	CbGeAlD
Amantadine—Dyspepsia—Paclitaxel—ovarian cancer	0.000384	0.00146	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000383	0.00146	CcSEcCtD
Amantadine—Neutropenia—Doxorubicin—ovarian cancer	0.00038	0.00145	CcSEcCtD
Amantadine—Decreased appetite—Paclitaxel—ovarian cancer	0.000379	0.00144	CcSEcCtD
Amantadine—Dry mouth—Docetaxel—ovarian cancer	0.000377	0.00144	CcSEcCtD
Amantadine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000377	0.00144	CcSEcCtD
Amantadine—Fatigue—Paclitaxel—ovarian cancer	0.000376	0.00143	CcSEcCtD
Amantadine—Constipation—Paclitaxel—ovarian cancer	0.000373	0.00142	CcSEcCtD
Amantadine—Confusional state—Docetaxel—ovarian cancer	0.000373	0.00142	CcSEcCtD
Amantadine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000371	0.00141	CcSEcCtD
Amantadine—Oedema—Docetaxel—ovarian cancer	0.00037	0.00141	CcSEcCtD
Amantadine—Anaphylactic shock—Docetaxel—ovarian cancer	0.00037	0.00141	CcSEcCtD
Amantadine—Agranulocytosis—Epirubicin—ovarian cancer	0.000365	0.00139	CcSEcCtD
Amantadine—Nervous system disorder—Docetaxel—ovarian cancer	0.000363	0.00138	CcSEcCtD
Amantadine—Tachycardia—Docetaxel—ovarian cancer	0.000361	0.00138	CcSEcCtD
Amantadine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00036	0.00137	CcSEcCtD
Amantadine—Skin disorder—Docetaxel—ovarian cancer	0.000359	0.00137	CcSEcCtD
Amantadine—Anorexia—Docetaxel—ovarian cancer	0.000353	0.00134	CcSEcCtD
Amantadine—Urinary tract disorder—Epirubicin—ovarian cancer	0.000347	0.00132	CcSEcCtD
Amantadine—Oedema peripheral—Epirubicin—ovarian cancer	0.000346	0.00132	CcSEcCtD
Amantadine—Hypotension—Docetaxel—ovarian cancer	0.000346	0.00132	CcSEcCtD
Amantadine—Body temperature increased—Paclitaxel—ovarian cancer	0.000345	0.00131	CcSEcCtD
Amantadine—Urethral disorder—Epirubicin—ovarian cancer	0.000344	0.00131	CcSEcCtD
Amantadine—Visual impairment—Epirubicin—ovarian cancer	0.000338	0.00129	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000338	0.00129	CcSEcCtD
Amantadine—Insomnia—Docetaxel—ovarian cancer	0.000335	0.00127	CcSEcCtD
Amantadine—Paraesthesia—Docetaxel—ovarian cancer	0.000332	0.00127	CcSEcCtD
Amantadine—Dyspnoea—Docetaxel—ovarian cancer	0.00033	0.00126	CcSEcCtD
Amantadine—Somnolence—Docetaxel—ovarian cancer	0.000329	0.00125	CcSEcCtD
Amantadine—Eye disorder—Epirubicin—ovarian cancer	0.000328	0.00125	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—ovarian cancer	0.000326	0.00124	CcSEcCtD
Amantadine—Dyspepsia—Docetaxel—ovarian cancer	0.000326	0.00124	CcSEcCtD
Amantadine—Decreased appetite—Docetaxel—ovarian cancer	0.000322	0.00122	CcSEcCtD
Amantadine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000322	0.00122	CcSEcCtD
Amantadine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000321	0.00122	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—ovarian cancer	0.00032	0.00122	CcSEcCtD
Amantadine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000319	0.00122	CcSEcCtD
Amantadine—Fatigue—Docetaxel—ovarian cancer	0.000319	0.00121	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—ovarian cancer	0.000319	0.00121	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—ovarian cancer	0.000319	0.00121	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—ovarian cancer	0.000316	0.00121	CcSEcCtD
Amantadine—Constipation—Docetaxel—ovarian cancer	0.000316	0.0012	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—ovarian cancer	0.000314	0.00119	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—ovarian cancer	0.000313	0.00119	CcSEcCtD
Amantadine—Asthenia—Paclitaxel—ovarian cancer	0.000313	0.00119	CcSEcCtD
Amantadine—Alopecia—Epirubicin—ovarian cancer	0.00031	0.00118	CcSEcCtD
Amantadine—Pruritus—Paclitaxel—ovarian cancer	0.000309	0.00118	CcSEcCtD
Amantadine—Mental disorder—Epirubicin—ovarian cancer	0.000308	0.00117	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—ovarian cancer	0.000306	0.00116	CcSEcCtD
Amantadine—Feeling abnormal—Docetaxel—ovarian cancer	0.000305	0.00116	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—ovarian cancer	0.000304	0.00116	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—ovarian cancer	0.000302	0.00115	CcSEcCtD
Amantadine—Tension—Epirubicin—ovarian cancer	0.0003	0.00114	CcSEcCtD
Amantadine—Diarrhoea—Paclitaxel—ovarian cancer	0.000299	0.00114	CcSEcCtD
Amantadine—Nervousness—Epirubicin—ovarian cancer	0.000297	0.00113	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—ovarian cancer	0.000295	0.00112	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000293	0.00112	CcSEcCtD
Amantadine—Body temperature increased—Docetaxel—ovarian cancer	0.000292	0.00111	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—ovarian cancer	0.00029	0.00111	CcSEcCtD
Amantadine—Dizziness—Paclitaxel—ovarian cancer	0.000289	0.0011	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—ovarian cancer	0.000288	0.0011	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—ovarian cancer	0.000287	0.00109	CcSEcCtD
Amantadine—Mental disorder—Doxorubicin—ovarian cancer	0.000285	0.00108	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—ovarian cancer	0.000283	0.00108	CcSEcCtD
Amantadine—Agitation—Epirubicin—ovarian cancer	0.000281	0.00107	CcSEcCtD
Amantadine—ABCB1—lymph node—ovarian cancer	0.000279	0.00391	CbGeAlD
Amantadine—Tension—Doxorubicin—ovarian cancer	0.000278	0.00106	CcSEcCtD
Amantadine—Vomiting—Paclitaxel—ovarian cancer	0.000277	0.00106	CcSEcCtD
Amantadine—Rash—Paclitaxel—ovarian cancer	0.000275	0.00105	CcSEcCtD
Amantadine—Dermatitis—Paclitaxel—ovarian cancer	0.000275	0.00105	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—ovarian cancer	0.000275	0.00105	CcSEcCtD
Amantadine—Leukopenia—Epirubicin—ovarian cancer	0.000274	0.00104	CcSEcCtD
Amantadine—Headache—Paclitaxel—ovarian cancer	0.000273	0.00104	CcSEcCtD
Amantadine—Hypersensitivity—Docetaxel—ovarian cancer	0.000273	0.00104	CcSEcCtD
Amantadine—Palpitations—Epirubicin—ovarian cancer	0.00027	0.00103	CcSEcCtD
Amantadine—Vision blurred—Doxorubicin—ovarian cancer	0.000267	0.00102	CcSEcCtD
Amantadine—Asthenia—Docetaxel—ovarian cancer	0.000265	0.00101	CcSEcCtD
Amantadine—Convulsion—Epirubicin—ovarian cancer	0.000265	0.00101	CcSEcCtD
Amantadine—Hypertension—Epirubicin—ovarian cancer	0.000264	0.00101	CcSEcCtD
Amantadine—Pruritus—Docetaxel—ovarian cancer	0.000262	0.000997	CcSEcCtD
Amantadine—Agitation—Doxorubicin—ovarian cancer	0.00026	0.00099	CcSEcCtD
Amantadine—Anxiety—Epirubicin—ovarian cancer	0.000259	0.000988	CcSEcCtD
Amantadine—Nausea—Paclitaxel—ovarian cancer	0.000259	0.000987	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000258	0.000984	CcSEcCtD
Amantadine—Dry mouth—Epirubicin—ovarian cancer	0.000255	0.000969	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—ovarian cancer	0.000253	0.000964	CcSEcCtD
Amantadine—Diarrhoea—Docetaxel—ovarian cancer	0.000253	0.000964	CcSEcCtD
Amantadine—Confusional state—Epirubicin—ovarian cancer	0.000252	0.000958	CcSEcCtD
Amantadine—Palpitations—Doxorubicin—ovarian cancer	0.00025	0.000952	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000249	0.00095	CcSEcCtD
Amantadine—Oedema—Epirubicin—ovarian cancer	0.000249	0.00095	CcSEcCtD
Amantadine—Convulsion—Doxorubicin—ovarian cancer	0.000245	0.000933	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—ovarian cancer	0.000245	0.000932	CcSEcCtD
Amantadine—Dizziness—Docetaxel—ovarian cancer	0.000245	0.000932	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—ovarian cancer	0.000244	0.00093	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—ovarian cancer	0.000243	0.000927	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—ovarian cancer	0.000242	0.000923	CcSEcCtD
Amantadine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000241	0.000919	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—ovarian cancer	0.00024	0.000914	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000239	0.000911	CcSEcCtD
Amantadine—Anorexia—Epirubicin—ovarian cancer	0.000238	0.000906	CcSEcCtD
Amantadine—Dry mouth—Doxorubicin—ovarian cancer	0.000236	0.000897	CcSEcCtD
Amantadine—Vomiting—Docetaxel—ovarian cancer	0.000235	0.000896	CcSEcCtD
Amantadine—Rash—Docetaxel—ovarian cancer	0.000233	0.000888	CcSEcCtD
Amantadine—Hypotension—Epirubicin—ovarian cancer	0.000233	0.000888	CcSEcCtD
Amantadine—Dermatitis—Docetaxel—ovarian cancer	0.000233	0.000888	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—ovarian cancer	0.000233	0.000887	CcSEcCtD
Amantadine—Headache—Docetaxel—ovarian cancer	0.000232	0.000883	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000231	0.000879	CcSEcCtD
Amantadine—Oedema—Doxorubicin—ovarian cancer	0.000231	0.000879	CcSEcCtD
Amantadine—Nervous system disorder—Doxorubicin—ovarian cancer	0.000226	0.000862	CcSEcCtD
Amantadine—Insomnia—Epirubicin—ovarian cancer	0.000226	0.000859	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—ovarian cancer	0.000225	0.000858	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—ovarian cancer	0.000224	0.000854	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—ovarian cancer	0.000224	0.000853	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000223	0.00085	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—ovarian cancer	0.000222	0.000847	CcSEcCtD
Amantadine—Somnolence—Epirubicin—ovarian cancer	0.000222	0.000845	CcSEcCtD
Amantadine—Anorexia—Doxorubicin—ovarian cancer	0.00022	0.000838	CcSEcCtD
Amantadine—Nausea—Docetaxel—ovarian cancer	0.00022	0.000837	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—ovarian cancer	0.00022	0.000836	CcSEcCtD
Amantadine—Decreased appetite—Epirubicin—ovarian cancer	0.000217	0.000826	CcSEcCtD
Amantadine—Hypotension—Doxorubicin—ovarian cancer	0.000216	0.000822	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000215	0.00082	CcSEcCtD
Amantadine—Fatigue—Epirubicin—ovarian cancer	0.000215	0.000819	CcSEcCtD
Amantadine—Constipation—Epirubicin—ovarian cancer	0.000213	0.000813	CcSEcCtD
Amantadine—Insomnia—Doxorubicin—ovarian cancer	0.000209	0.000795	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—ovarian cancer	0.000207	0.00079	CcSEcCtD
Amantadine—Dyspnoea—Doxorubicin—ovarian cancer	0.000206	0.000784	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—ovarian cancer	0.000206	0.000783	CcSEcCtD
Amantadine—Somnolence—Doxorubicin—ovarian cancer	0.000205	0.000782	CcSEcCtD
Amantadine—Dyspepsia—Doxorubicin—ovarian cancer	0.000203	0.000774	CcSEcCtD
Amantadine—Decreased appetite—Doxorubicin—ovarian cancer	0.000201	0.000764	CcSEcCtD
Amantadine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000199	0.000759	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—ovarian cancer	0.000199	0.000758	CcSEcCtD
Amantadine—Constipation—Doxorubicin—ovarian cancer	0.000197	0.000752	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—ovarian cancer	0.000197	0.000751	CcSEcCtD
Amantadine—Feeling abnormal—Doxorubicin—ovarian cancer	0.00019	0.000725	CcSEcCtD
Amantadine—Hypersensitivity—Epirubicin—ovarian cancer	0.000184	0.0007	CcSEcCtD
Amantadine—Body temperature increased—Doxorubicin—ovarian cancer	0.000182	0.000695	CcSEcCtD
Amantadine—Asthenia—Epirubicin—ovarian cancer	0.000179	0.000682	CcSEcCtD
Amantadine—Pruritus—Epirubicin—ovarian cancer	0.000177	0.000672	CcSEcCtD
Amantadine—Diarrhoea—Epirubicin—ovarian cancer	0.000171	0.00065	CcSEcCtD
Amantadine—Hypersensitivity—Doxorubicin—ovarian cancer	0.00017	0.000648	CcSEcCtD
Amantadine—Asthenia—Doxorubicin—ovarian cancer	0.000166	0.000631	CcSEcCtD
Amantadine—Dizziness—Epirubicin—ovarian cancer	0.000165	0.000628	CcSEcCtD
Amantadine—Pruritus—Doxorubicin—ovarian cancer	0.000163	0.000622	CcSEcCtD
Amantadine—Vomiting—Epirubicin—ovarian cancer	0.000159	0.000604	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—ovarian cancer	0.000158	0.000602	CcSEcCtD
Amantadine—Rash—Epirubicin—ovarian cancer	0.000157	0.000599	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—ovarian cancer	0.000157	0.000599	CcSEcCtD
Amantadine—Headache—Epirubicin—ovarian cancer	0.000156	0.000595	CcSEcCtD
Amantadine—Dizziness—Doxorubicin—ovarian cancer	0.000153	0.000581	CcSEcCtD
Amantadine—Nausea—Epirubicin—ovarian cancer	0.000148	0.000564	CcSEcCtD
Amantadine—Vomiting—Doxorubicin—ovarian cancer	0.000147	0.000559	CcSEcCtD
Amantadine—Rash—Doxorubicin—ovarian cancer	0.000146	0.000554	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—ovarian cancer	0.000145	0.000554	CcSEcCtD
Amantadine—Headache—Doxorubicin—ovarian cancer	0.000145	0.000551	CcSEcCtD
Amantadine—Nausea—Doxorubicin—ovarian cancer	0.000137	0.000522	CcSEcCtD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—ovarian cancer	8.79e-05	0.000632	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP2—ovarian cancer	8.74e-05	0.000629	CbGpPWpGaD
Amantadine—MAOB—Metabolism—YAP1—ovarian cancer	8.72e-05	0.000627	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	8.58e-05	0.000617	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—ovarian cancer	8.57e-05	0.000616	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	8.56e-05	0.000616	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CASP3—ovarian cancer	8.56e-05	0.000615	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL2—ovarian cancer	8.54e-05	0.000614	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP2—ovarian cancer	8.52e-05	0.000613	CbGpPWpGaD
Amantadine—DDC—Metabolism—FASN—ovarian cancer	8.45e-05	0.000607	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—DLC1—ovarian cancer	8.4e-05	0.000604	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—MAPK1—ovarian cancer	8.39e-05	0.000603	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	8.38e-05	0.000603	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	8.31e-05	0.000598	CbGpPWpGaD
Amantadine—DDC—Metabolism—SLC5A5—ovarian cancer	8.31e-05	0.000597	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—VEGFA—ovarian cancer	8.27e-05	0.000594	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	8.21e-05	0.00059	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—MAPK1—ovarian cancer	8.18e-05	0.000588	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NRAS—ovarian cancer	8.17e-05	0.000587	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	8.16e-05	0.000587	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—VEGFA—ovarian cancer	8.06e-05	0.00058	CbGpPWpGaD
Amantadine—DDC—Metabolism—SLC2A1—ovarian cancer	8.02e-05	0.000577	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NRAS—ovarian cancer	7.96e-05	0.000572	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.92e-05	0.00057	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYTB—ovarian cancer	7.89e-05	0.000568	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MAPK3—ovarian cancer	7.82e-05	0.000562	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—HRAS—ovarian cancer	7.72e-05	0.000555	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP1B1—ovarian cancer	7.69e-05	0.000553	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—ERBB2—ovarian cancer	7.66e-05	0.000551	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.65e-05	0.00055	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MAPK3—ovarian cancer	7.62e-05	0.000548	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—ERBB2—ovarian cancer	7.47e-05	0.000537	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MAPK1—ovarian cancer	7.44e-05	0.000535	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—EGFR—ovarian cancer	7.44e-05	0.000535	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.38e-05	0.000531	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYTB—ovarian cancer	7.36e-05	0.000529	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	7.26e-05	0.000522	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MAPK1—ovarian cancer	7.25e-05	0.000522	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—ovarian cancer	7.25e-05	0.000522	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.13e-05	0.000513	CbGpPWpGaD
Amantadine—MAOB—Metabolism—FASN—ovarian cancer	7.11e-05	0.000511	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—ovarian cancer	7.03e-05	0.000505	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SLC5A5—ovarian cancer	6.99e-05	0.000503	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPP1CC—ovarian cancer	6.9e-05	0.000496	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—BRIP1—ovarian cancer	6.9e-05	0.000496	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—ovarian cancer	6.85e-05	0.000493	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BCL9—ovarian cancer	6.85e-05	0.000493	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPP2R1A—ovarian cancer	6.82e-05	0.000491	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SLC2A1—ovarian cancer	6.75e-05	0.000486	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—ovarian cancer	6.73e-05	0.000484	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CTNNB1—ovarian cancer	6.7e-05	0.000482	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NME2—ovarian cancer	6.69e-05	0.000481	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP9—ovarian cancer	6.57e-05	0.000472	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—ovarian cancer	6.56e-05	0.000472	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CTNNB1—ovarian cancer	6.53e-05	0.00047	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	6.49e-05	0.000466	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP1B1—ovarian cancer	6.47e-05	0.000466	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—BRIP1—ovarian cancer	6.43e-05	0.000462	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPP1CC—ovarian cancer	6.43e-05	0.000462	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP9—ovarian cancer	6.4e-05	0.000461	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	6.34e-05	0.000456	CbGpPWpGaD
Amantadine—DDC—Metabolism—ABCB1—ovarian cancer	6.33e-05	0.000456	CbGpPWpGaD
Amantadine—DDC—Metabolism—TYMS—ovarian cancer	6.22e-05	0.000447	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PTEN—ovarian cancer	6.15e-05	0.000442	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	6.04e-05	0.000434	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCL8—ovarian cancer	6.04e-05	0.000434	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	5.99e-05	0.000431	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—ovarian cancer	5.97e-05	0.00043	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—VEGFA—ovarian cancer	5.9e-05	0.000424	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—STAT3—ovarian cancer	5.84e-05	0.00042	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NRAS—ovarian cancer	5.83e-05	0.000419	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—ovarian cancer	5.82e-05	0.000419	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—VEGFA—ovarian cancer	5.75e-05	0.000414	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPP2R1A—ovarian cancer	5.74e-05	0.000413	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—IL6—ovarian cancer	5.72e-05	0.000411	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—STAT3—ovarian cancer	5.69e-05	0.000409	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	5.69e-05	0.000409	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NRAS—ovarian cancer	5.68e-05	0.000408	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.63e-05	0.000405	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MAPK3—ovarian cancer	5.58e-05	0.000401	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—IL6—ovarian cancer	5.57e-05	0.000401	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MAPK3—ovarian cancer	5.44e-05	0.000391	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—DOK1—ovarian cancer	5.42e-05	0.000389	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	5.35e-05	0.000385	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ABCB1—ovarian cancer	5.33e-05	0.000383	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MAPK1—ovarian cancer	5.31e-05	0.000382	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—ovarian cancer	5.31e-05	0.000382	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	5.3e-05	0.000381	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TYMS—ovarian cancer	5.24e-05	0.000377	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MAPK1—ovarian cancer	5.18e-05	0.000372	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—ovarian cancer	5.18e-05	0.000372	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PPP1CC—ovarian cancer	5.09e-05	0.000366	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—ovarian cancer	5.02e-05	0.000361	CbGpPWpGaD
Amantadine—DDC—Metabolism—CAV1—ovarian cancer	5.01e-05	0.000361	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—ovarian cancer	4.89e-05	0.000352	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	4.8e-05	0.000345	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	4.65e-05	0.000335	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—YAP1—ovarian cancer	4.63e-05	0.000333	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—ovarian cancer	4.57e-05	0.000329	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CG—ovarian cancer	4.57e-05	0.000328	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—MAPK1—ovarian cancer	4.36e-05	0.000314	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.33e-05	0.000311	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—YAP1—ovarian cancer	4.31e-05	0.00031	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYTB—ovarian cancer	4.31e-05	0.00031	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	4.31e-05	0.00031	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—ovarian cancer	4.26e-05	0.000307	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—ovarian cancer	4.26e-05	0.000306	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.22e-05	0.000304	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CAV1—ovarian cancer	4.22e-05	0.000303	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—ovarian cancer	4.2e-05	0.000302	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.18e-05	0.000301	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—ovarian cancer	4.16e-05	0.000299	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.11e-05	0.000296	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—IL6—ovarian cancer	4.08e-05	0.000293	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.07e-05	0.000293	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—MAPK1—ovarian cancer	4.06e-05	0.000292	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CD—ovarian cancer	4.01e-05	0.000289	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—IL6—ovarian cancer	3.98e-05	0.000286	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.97e-05	0.000285	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HDAC6—ovarian cancer	3.86e-05	0.000277	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CG—ovarian cancer	3.84e-05	0.000276	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—IL6—ovarian cancer	3.84e-05	0.000276	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PPP2R1A—ovarian cancer	3.81e-05	0.000274	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—FASN—ovarian cancer	3.77e-05	0.000271	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPP1CC—ovarian cancer	3.77e-05	0.000271	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BRIP1—ovarian cancer	3.77e-05	0.000271	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—ovarian cancer	3.76e-05	0.000271	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC5A5—ovarian cancer	3.71e-05	0.000267	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—ovarian cancer	3.67e-05	0.000264	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL8—ovarian cancer	3.66e-05	0.000263	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC2A1—ovarian cancer	3.58e-05	0.000258	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.58e-05	0.000258	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—FASN—ovarian cancer	3.52e-05	0.000253	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—ovarian cancer	3.5e-05	0.000252	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CB—ovarian cancer	3.5e-05	0.000252	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC5A5—ovarian cancer	3.46e-05	0.000249	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP1B1—ovarian cancer	3.44e-05	0.000247	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—YAP1—ovarian cancer	3.42e-05	0.000246	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.39e-05	0.000244	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CD—ovarian cancer	3.38e-05	0.000243	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—XIAP—ovarian cancer	3.35e-05	0.000241	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC2A1—ovarian cancer	3.34e-05	0.00024	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.3e-05	0.000237	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—ovarian cancer	3.26e-05	0.000235	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SMARCA4—ovarian cancer	3.26e-05	0.000234	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.23e-05	0.000232	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.22e-05	0.000232	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP1B1—ovarian cancer	3.2e-05	0.00023	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EREG—ovarian cancer	3.18e-05	0.000229	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPP2R1A—ovarian cancer	3.05e-05	0.000219	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.05e-05	0.000219	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—ovarian cancer	3.02e-05	0.000217	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PGR—ovarian cancer	2.98e-05	0.000214	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CB—ovarian cancer	2.95e-05	0.000212	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPP2R1A—ovarian cancer	2.84e-05	0.000204	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ABCB1—ovarian cancer	2.83e-05	0.000203	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CG—ovarian cancer	2.81e-05	0.000202	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.8e-05	0.000201	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TYMS—ovarian cancer	2.78e-05	0.0002	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PARP1—ovarian cancer	2.77e-05	0.000199	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.71e-05	0.000195	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6ST—ovarian cancer	2.65e-05	0.000191	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ABCB1—ovarian cancer	2.64e-05	0.00019	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TYMS—ovarian cancer	2.59e-05	0.000186	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CG—ovarian cancer	2.55e-05	0.000183	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—ovarian cancer	2.54e-05	0.000183	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—YAP1—ovarian cancer	2.53e-05	0.000182	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CD—ovarian cancer	2.47e-05	0.000177	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.29e-05	0.000164	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PPP2R1A—ovarian cancer	2.25e-05	0.000162	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CD—ovarian cancer	2.24e-05	0.000161	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CAV1—ovarian cancer	2.24e-05	0.000161	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CB—ovarian cancer	2.15e-05	0.000155	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—ovarian cancer	2.13e-05	0.000153	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CAV1—ovarian cancer	2.09e-05	0.00015	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL8—ovarian cancer	2.07e-05	0.000149	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—FASN—ovarian cancer	2.06e-05	0.000148	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CG—ovarian cancer	2.04e-05	0.000147	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC5A5—ovarian cancer	2.03e-05	0.000146	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—ovarian cancer	1.97e-05	0.000142	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.96e-05	0.000141	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CB—ovarian cancer	1.95e-05	0.00014	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CG—ovarian cancer	1.9e-05	0.000137	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.88e-05	0.000135	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL8—ovarian cancer	1.88e-05	0.000135	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—ovarian cancer	1.8e-05	0.000129	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CD—ovarian cancer	1.79e-05	0.000129	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—ovarian cancer	1.79e-05	0.000129	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—ovarian cancer	1.79e-05	0.000128	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—ovarian cancer	1.74e-05	0.000125	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CD—ovarian cancer	1.67e-05	0.00012	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.66e-05	0.00012	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CAV1—ovarian cancer	1.65e-05	0.000119	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ESR1—ovarian cancer	1.59e-05	0.000115	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6ST—ovarian cancer	1.57e-05	0.000113	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CB—ovarian cancer	1.56e-05	0.000112	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TYMS—ovarian cancer	1.52e-05	0.000109	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APC—ovarian cancer	1.51e-05	0.000108	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CG—ovarian cancer	1.51e-05	0.000108	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—ovarian cancer	1.51e-05	0.000108	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—ovarian cancer	1.47e-05	0.000105	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CB—ovarian cancer	1.46e-05	0.000105	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK3—ovarian cancer	1.44e-05	0.000104	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK1—ovarian cancer	1.37e-05	9.86e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—ovarian cancer	1.37e-05	9.86e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—ovarian cancer	1.35e-05	9.71e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CD—ovarian cancer	1.32e-05	9.52e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—ovarian cancer	1.31e-05	9.42e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—ovarian cancer	1.3e-05	9.32e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—ovarian cancer	1.26e-05	9.05e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CAV1—ovarian cancer	1.22e-05	8.8e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	1.19e-05	8.56e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—ovarian cancer	1.17e-05	8.4e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MTOR—ovarian cancer	1.15e-05	8.29e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	1.15e-05	8.29e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.11e-05	8.01e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL8—ovarian cancer	1.11e-05	7.97e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—ovarian cancer	1.1e-05	7.92e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	1.08e-05	7.78e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	1.07e-05	7.7e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP3—ovarian cancer	1.06e-05	7.63e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—ovarian cancer	1.06e-05	7.62e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—ovarian cancer	1.05e-05	7.58e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.03e-05	7.43e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.02e-05	7.35e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—ovarian cancer	1e-05	7.21e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—ovarian cancer	9.97e-06	7.17e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CD—ovarian cancer	9.8e-06	7.04e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	9.72e-06	6.99e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—ovarian cancer	9.53e-06	6.85e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	9e-06	6.47e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—ovarian cancer	8.91e-06	6.41e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—ovarian cancer	8.89e-06	6.39e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—ovarian cancer	8.88e-06	6.39e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CB—ovarian cancer	8.54e-06	6.14e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	8.52e-06	6.12e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—ovarian cancer	8.28e-06	5.96e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	8.1e-06	5.83e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—ovarian cancer	8.1e-06	5.83e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—ovarian cancer	7.78e-06	5.6e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—ovarian cancer	7.65e-06	5.5e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—ovarian cancer	7.38e-06	5.31e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—ovarian cancer	7.25e-06	5.22e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	7.03e-06	5.06e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—ovarian cancer	6.8e-06	4.89e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—ovarian cancer	6.5e-06	4.68e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—ovarian cancer	6.23e-06	4.48e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—ovarian cancer	5.74e-06	4.13e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—ovarian cancer	5.2e-06	3.74e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—ovarian cancer	4.25e-06	3.06e-05	CbGpPWpGaD
